Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in Colorado: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 875 | 46% |
| 2020 | 2 | 760 | 48% |
| 2021 | 2 | 808 | 50% |
| 2022 | 3 | 794 | 53% |
| 2023 | 1 | 753 | 55% |
| 2024 | 2 | 764 | 57% |
| 2025 from claims | – | 783 633–919 | 57% |
| 2026 forecast | – | 814 638–1,022 | 56% |
| 2027 forecast | – | 826 613–1,092 | 56% |
| 2028 forecast | – | 839 594–1,157 | 57% |
| 2029 forecast | – | 851 578–1,220 | 57% |
| 2030 forecast | – | 864 566–1,282 | 57% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Colorado; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 16 | 4,592−1.4%/yr | −1.4%/yr | 1.4 | 0% | 5,470 in 2030+3%/yr |
| Arizona | 9 | 1,209−3.2%/yr | −3.2%/yr | 1.7 | 0% | 1,270 in 2030+0.9%/yr |
| Washington | 4 | 1,073−5.1%/yr | −5.1%/yr | 1.4 | 0% | 1,020 in 2030−0.9%/yr |
| Oregon | 1 | 627−4.1%/yr | −4.1%/yr | 1.5 | 0% | 710 in 2030+2%/yr |
| Nevada | 3 | 409−3.9%/yr | −3.9%/yr | 1.5 | 0% | 440 in 2030+1.1%/yr |
| Utah | 1 | 352−0.3%/yr | −0.3%/yr | 1.6 | 0% | 360 in 2030+0.4%/yr |
| Montana | 2 | 340−0.4%/yr | −0.4%/yr | 1.8 | 0% | 360 in 2030+1%/yr |
| Idaho | 0 | 307−1.1%/yr | −1.1%/yr | 1.5 | 0% | 320 in 2030+0.6%/yr |
| New Mexico | 0 | 182−11%/yr | −11%/yr | 0.8 | 0% | 170 in 2030−1.5%/yr |
| Alaska | 0 | 161−1.8%/yr | −1.8%/yr | 1.3 | 0% | 170 in 2030+1.2%/yr |
| Wyoming | 0 | 105−1.1%/yr | −1.1%/yr | 1.0 | 0% | 110 in 2030+0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 52 | 3,413−0.2%/yr | −0.2%/yr | 7.41.3× | 11% | 3,950 in 2030+2.5%/yr |
| Cholecystectomy & appendectomy | 18 | 1,923−3.3%/yr | −3.3%/yr | 4.11.1× | 3% | 2,250 in 2030+2.6%/yr |
| Antireflux & hiatal hernia surgery | 10 | 529+3.9%/yr | +3.9%/yr | 1.11.6× | 0% | 750 in 2030+6.1%/yr |
| Breast reconstruction | 0 | 223−9.1%/yr | −9.1%/yr | 0.51.1× | 0% | 230 in 2030+0.5%/yr |
Colorectal resection in every state, and its device makers · Every procedure market in Colorado · Every state · Compare with California
Intuitive Surgical leads with 61% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 4 companies reported engagement with Colorado’s surgeons worth $328K in consulting, speaking, meals and travel tied to these products, about $164K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.